These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 19844105)

  • 1. Cerebrospinal fluid total tau is associated with shorter survival in dementia with Lewy bodies.
    Boström F; Hansson O; Blennow K; Gerhardsson L; Lundh T; Minthon L; Zetterberg H; Londos E
    Dement Geriatr Cogn Disord; 2009; 28(4):314-9. PubMed ID: 19844105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies.
    Parnetti L; Tiraboschi P; Lanari A; Peducci M; Padiglioni C; D'Amore C; Pierguidi L; Tambasco N; Rossi A; Calabresi P
    Biol Psychiatry; 2008 Nov; 64(10):850-5. PubMed ID: 18395699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease.
    Gómez-Tortosa E; Gonzalo I; Fanjul S; Sainz MJ; Cantarero S; Cemillán C; Yébenes JG; del Ser T
    Arch Neurol; 2003 Sep; 60(9):1218-22. PubMed ID: 12975286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CSF tau, Aβ42, and MHPG differentiate dementia with Lewy bodies from Alzheimer's disease.
    Aerts MB; Esselink RA; Claassen JA; Abdo WF; Bloem BR; Verbeek MM
    J Alzheimers Dis; 2011; 27(2):377-84. PubMed ID: 21841257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?
    Clark CM; Xie S; Chittams J; Ewbank D; Peskind E; Galasko D; Morris JC; McKeel DW; Farlow M; Weitlauf SL; Quinn J; Kaye J; Knopman D; Arai H; Doody RS; DeCarli C; Leight S; Lee VM; Trojanowski JQ
    Arch Neurol; 2003 Dec; 60(12):1696-702. PubMed ID: 14676043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum heart-type fatty acid-binding protein and cerebrospinal fluid tau: marker candidates for dementia with Lewy bodies.
    Mollenhauer B; Steinacker P; Bahn E; Bibl M; Brechlin P; Schlossmacher MG; Locascio JJ; Wiltfang J; Kretzschmar HA; Poser S; Trenkwalder C; Otto M
    Neurodegener Dis; 2007; 4(5):366-75. PubMed ID: 17622779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CSF alpha-synuclein levels in dementia with Lewy bodies and Alzheimer's disease.
    Noguchi-Shinohara M; Tokuda T; Yoshita M; Kasai T; Ono K; Nakagawa M; El-Agnaf OM; Yamada M
    Brain Res; 2009 Jan; 1251():1-6. PubMed ID: 19071095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal fluid neuron-specific enolase: a further marker of Alzheimer's disease?
    Palumbo B; Siepi D; Sabalich I; Tranfaglia C; Parnetti L
    Funct Neurol; 2008; 23(2):93-6. PubMed ID: 18671910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced CSF CART in dementia with Lewy bodies.
    Schultz K; Wiehager S; Nilsson K; Nielsen JE; Lindquist SG; Hjermind LE; Andersen BB; Wallin A; Nilsson C; Petersén A
    Neurosci Lett; 2009 Apr; 453(2):104-6. PubMed ID: 19356602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CSF Mg and Ca as diagnostic markers for dementia with Lewy bodies.
    Boström F; Hansson O; Gerhardsson L; Lundh T; Minthon L; Stomrud E; Zetterberg H; Londos E
    Neurobiol Aging; 2009 Aug; 30(8):1265-71. PubMed ID: 18191875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study.
    Hampel H; Buerger K; Zinkowski R; Teipel SJ; Goernitz A; Andreasen N; Sjoegren M; DeBernardis J; Kerkman D; Ishiguro K; Ohno H; Vanmechelen E; Vanderstichele H; McCulloch C; Moller HJ; Davies P; Blennow K
    Arch Gen Psychiatry; 2004 Jan; 61(1):95-102. PubMed ID: 14706948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CSF α-synuclein does not discriminate dementia with Lewy bodies from Alzheimer's disease.
    Reesink FE; Lemstra AW; van Dijk KD; Berendse HW; van de Berg WD; Klein M; Blankenstein MA; Scheltens P; Verbeek MM; van der Flier WM
    J Alzheimers Dis; 2010; 22(1):87-95. PubMed ID: 20847452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tau protein, Abeta42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies.
    Mollenhauer B; Cepek L; Bibl M; Wiltfang J; Schulz-Schaeffer WJ; Ciesielczyk B; Neumann M; Steinacker P; Kretzschmar HA; Poser S; Trenkwalder C; Otto M
    Dement Geriatr Cogn Disord; 2005; 19(2-3):164-70. PubMed ID: 15637452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CSF amyloid-β peptides in neuropathologically diagnosed dementia with Lewy bodies and Alzheimer's disease.
    Mollenhauer B; Esselmann H; Trenkwalder C; Schulz-Schaeffer W; Kretzschmar H; Otto M; Wiltfang J; Bibl M
    J Alzheimers Dis; 2011; 24(2):383-91. PubMed ID: 21297274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlations of CSF tau and amyloid levels with Alzheimer pathology in neuropathologically verified dementia with Lewy bodies.
    Brunnström H; Hansson O; Zetterberg H; Londos E; Englund E
    Int J Geriatr Psychiatry; 2013 Jul; 28(7):738-44. PubMed ID: 22911491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
    Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
    Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of amyloid-beta peptides in CSF diagnosis of neurodegenerative dementias.
    Bibl M; Mollenhauer B; Lewczuk P; Esselmann H; Wolf S; Trenkwalder C; Otto M; Stiens G; Rüther E; Kornhuber J; Wiltfang J
    Mol Psychiatry; 2007 Jul; 12(7):671-80. PubMed ID: 17339876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival and mortality differences between dementia with Lewy bodies vs Alzheimer disease.
    Williams MM; Xiong C; Morris JC; Galvin JE
    Neurology; 2006 Dec; 67(11):1935-41. PubMed ID: 17159097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuropsychological and behavioural correlates of CSF biomarkers in dementia.
    Engelborghs S; Maertens K; Vloeberghs E; Aerts T; Somers N; Mariën P; De Deyn PP
    Neurochem Int; 2006 Mar; 48(4):286-95. PubMed ID: 16434124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer's disease and dementia with Lewy bodies.
    Luo X; Hou L; Shi H; Zhong X; Zhang Y; Zheng D; Tan Y; Hu G; Mu N; Chan J; Chen X; Fang Y; Wu F; He H; Ning Y
    J Neurochem; 2013 Dec; 127(5):681-90. PubMed ID: 23800322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.